Clinical Scorecard: Advancements and Future Considerations in Urethra-Sparing Stereotactic Body Radiotherapy for Prostate Cancer: A Comprehensive Literature Review

At a Glance

Key Highlights

• Technological advances in IMRT, rotational techniques, and IGRT have improved toxicity profiles in prostate radiotherapy.
• Hypofractionated SBRT schedules (≤5 fractions) are increasingly standard for localized prostate cancer treatment.
• Urethra-sparing techniques, including urethra-steering and urethra dose-reduction, are emerging to reduce genitourinary toxicity associated with SBRT.

Guideline-Based Recommendations

Diagnosis

• Confirm localized prostate cancer diagnosis prior to SBRT treatment planning.

Management

• Implement urethra-sparing SBRT techniques by applying dose constraints to the urethra during treatment planning.
• Use either urethra-steering (restricting hotspots to urethra) or urethra dose-reduction (maximal urethral dose below prostate prescription dose).
• Consider simultaneous integrated boost (SIB) to dominant intraprostatic lesions while respecting urethral dose constraints.

Monitoring & Follow-up

• Assess acute and late genitourinary toxicity using standardized grading scales such as RTOG or CTCAE.
• Monitor urinary function and quality of life post-treatment with validated questionnaires (e.g., IPSS, EORTC QoL PR-25).
• Follow patients longitudinally to detect and manage urinary toxicity flare-ups.

Risks

• Genitourinary toxicity is multifactorial and influenced by age, baseline urinary function, prostate size, and urethral radiation dose.
• Higher urethral doses correlate with increased risk of acute and late grade 2 GU toxicity.
• Risk of acute urinary retention requiring catheterization exists, particularly with higher dose escalation.

Patient & Prescribing Data

Men with localized prostate cancer undergoing SBRT with urethra-sparing techniques

Dose constraints to the urethra (e.g., Dmax ≤42 Gy or EQD2 ~85 Gy) are associated with acceptable acute and late GU toxicity rates; treatment schedules (weekly vs semi-weekly) impact toxicity incidence.

Clinical Best Practices

• Define urethra precisely as an organ at risk during treatment planning to optimize dose sparing.
• Apply consistent and protocol-defined urethral dose constraints to minimize GU toxicity.
• Consider treatment fractionation schedules carefully, as shorter overall treatment times may increase acute GU toxicity.
• Use prospective toxicity and quality of life assessments to guide patient management and refine protocols.

References

• McDonald et al. Prospective pilot study on urethra-steering SBRT
• Hypo-FLAME trial on urethra dose constraints in SBRT
• Cloitre et al. Phase I-II dose escalation trial with CyberKnife®